Boehringer Ingelheim Exercises Option in Therapeutic MorphoSys by liaoqinmei

VIEWS: 6 PAGES: 2

									Press Release
Ingelheim and Martinsried/Munich, Germany, November 18, 2003


      Boehringer Ingelheim Exercises Option in Therapeutic
             Antibody Collaboration with MorphoSys

Boehringer Ingelheim and MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime
Standard Segment) today announced that Boehringer Ingelheim has exercised its first
option for the development of a therapeutic antibody. MorphoSys will develop a
therapeutic antibody for Boehringer Ingelheim against an undisclosed target molecule for
the treatment of inflammatory diseases such as asthma and rheumatoid arthritis.
MorphoSys is to select the antibody from the HuCAL® GOLD library. Boehringer Ingelheim
will take over the pre-clinical and clinical development and the subsequent marketing of
the resultant products on which MorphoSys will earn milestones and royalties. Financial
details were not disclosed.
Boehringer Ingelheim and MorphoSys agreed to a cooperation in the field of therapeutic
antibodies in February 2003. In the context of these agreements, MorphoSys received the
exclusive, global license for certain patents owned by or under the control of Boehringer
Ingelheim. Specifically, MorphoSys acquired the rights to develop, produce and sell
therapeutic and diagnostic antibodies that target ICAM-1 (intercellular adhesion molecule).
In the context of its own development programs, MorphoSys is developing MOR101 and
MOR102, antibodies against ICAM-1, for the treatment of inflammatory diseases such as
psoriasis or dermal burns. MorphoSys will make milestone and royalty payments to
Boehringer Ingelheim for the sale of therapeutic or diagnostic antibodies against ICAM-1.
In exchange, Boehringer Ingelheim received exclusive licenses for therapeutic antibodies
against two undisclosed target molecules. Boehringer Ingelheim will make milestone and
royalty payments to MorphoSys for the development and sale of HuCAL® GOLD antibodies
produced by MorphoSys.
"We are pleased to utilize the distinct advantages of the HuCAL® technology developed by
MorphoSys to rapidly identify therapeutically active antibodies to this unique target
molecule", said Dr Andreas Barner, Member of the Board of Managing Directors and Head
of Research, Development and Medicine at Boehringer Ingelheim. "This collaboration will
strengthen our capability to further generate innovative new biological entities for the
treatment of autoimmune and inflammatory diseases."
“We look forward to working with Boehringer Ingelheim to develop a human therapeutic
antibody against this very interesting target,” commented Dr Simon Moroney, Chief
Executive Officer at MorphoSys AG. “We are delighted with our relationship with
Boehringer Ingelheim, which has given us exclusive rights to antibodies against ICAM-1 as
well as, with the current project, a further opportunity to broaden our pipeline of
partnered compounds.”
About MorphoSys:
MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which
accelerate drug discovery and target characterization. Founded in 1992, the Company's proprietary Human
Combinatorial Antibody Library (HuCAL) technology is used by researchers worldwide for human antibody
generation. The Company currently has licensing and research collaborations with Bayer (Berkeley,
California/USA), Biogen Inc. (Cambridge, Massachusetts/USA), Boehringer Ingelheim (Ingelheim, Germany),
Bristol-Myers Squibb (Wilmington, Delaware/USA), Centocor Inc. (Malvern, Pennsylvania/USA),
California/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen
Inc. (Cambridge, Massachusetts/USA), Oridis Biomed GmbH (Graz/Austria), ProChon Biotech Ltd.
(Rehovot/Israel), Schering AG (Berlin/Germany) and Xoma Ltd. (Berkeley, California/USA). For further
information please visit the corporate website at: http://www.morphosys.com/.

About Boehringer Ingelheim:
The Boehringer Ingelheim Corporation is one of the world’s 20 leading pharmaceutical companies.
Headquartered in Ingelheim, Germany, it operates globally with 156 affiliates in 44 countries and more than
32,000 employees. Since it was founded in 1885, the family-owned company has been committed to
researching, manufacturing and marketing novel products of high therapeutic value for human and veterinary
medicine.
In 2002, Boehringer Ingelheim posted net sales of 7.6 billion euro while spending about one fifth of net sales
in its largest business segment Prescription Medicines on research and development.
For further information about Boehringer Ingelheim please visit <www.boehringer-ingelheim.com>.



Statements included in this press release which are not historical in nature are intended to be, and are hereby
identified as, “forward-looking statements” for purposes of the safe harbour provided by Section 21E of the
Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”,
“estimates”, “expects” and similar expressions. The company cautions readers that forward-looking
statements, including without limitation those relating to the company’s future operations and business
prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially
from those indicated in the forward-looking statements. Factors that may affect future operations and
business prospects include, but are not limited to, clinical and scientific results and developments concerning
corporate collaborations and the company’s proprietary rights and other factors described in the prospectus
relating to the company’s recent public offering.

For more information, please contact:
MorphoSys AG:
Dave Lemus                                             Dr. Claudia Gutjahr-Löser
Chief Financial Officer                                Manager Corporate Communications
Phone: +49 (0) 89 / 899 27-439                         Phone: +49 (0) 89 / 899 27-122
Fax: +49 (0) 89 / 899 27-5439                          Fax: +49 (0) 89 / 899 27-5122
investors@morphosys.com                                gutjahr-loeser@morphosys.com

Boehringer Ingelheim:
Kerstin Felix
Corporate Division Communications
Boehringer Ingelheim GmbH
55216 Ingelheim/Germany
Phone: +49 (0) 6132 / 77 9040
Fax: +49 (0) 6132 / 77 6601
Kerstin.Felix@ing.boehringer-ingelheim.com

								
To top